{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T05:09:24Z","timestamp":1775797764073,"version":"3.50.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Despite initial responses, resistance to tyrosine kinase inhibitors (TKIs) and disease relapse remain major challenges in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph\n                      <jats:sup>+<\/jats:sup>\n                      ALL). Given the efficacy of chimeric antigen receptor T (CAR-T) cell therapy in Relapsed\/Refractory (R\/R) ALL, we aimed to evaluate the long-term outcomes of co-administration of CD19 and CD22 CAR-T cell therapy for pediatric patients with R\/R Ph\n                      <jats:sup>+<\/jats:sup>\n                      ALL.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a retrospective subanalysis of patients with R\/R Ph\n                      <jats:sup>+<\/jats:sup>\n                      ALL to assess the long-term outcomes of co-administration of CD19 and CD22 CAR-T cell therapy. Complete hematologic remission (CHR), measurable residual disease-negative complete remission (MRD\n                      <jats:sup>\u2212<\/jats:sup>\n                      CR), complete molecular remission (CMR), relapse-free survival (RFS), and overall survival (OS) were among the important outcomes that were evaluated with a data cutoff of October 1, 2025.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Within 1 month after CAR-T cell infusion, all patients achieved CHR, with MRD\n                      <jats:sup>\u2212<\/jats:sup>\n                      CR and CMR of 100 and 77.8%, respectively. Two patients underwent consolidative allogeneic stem cell transplant (allo-HSCT). Notably, six patients achieved sustained CHR without allo-HSCT. At a median follow-up of 54.93\u202fmonths (range, 16.83\u201371.6\u202fmonths), the 4-year OS and RFS were 91.7 and 66.7%. No treatment-related deaths occurred from CAR-T toxicity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      These preliminary findings suggest that CD19 and CD22 CAR-T cell therapy may provide long-term survival benefits in pediatric patients with R\/R Ph\n                      <jats:sup>+<\/jats:sup>\n                      ALL, with manageable toxicity. However, these results should be considered hypothesis-generating and require validation in larger, controlled studies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.chictr.org.cn\/showproj.html?proj=52403<\/jats:ext-link>\n                      , ChiCTR2000032211.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1815353","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T04:27:31Z","timestamp":1775795251000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term outcomes of co-administration of CD19 and CD22 CAR-T cell therapy in pediatric patients with relapsed\/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia"],"prefix":"10.3389","volume":"13","author":[{"given":"Zichao","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Hematology\/Oncology, National Health Committee Key Laboratory of Pediatric Hematology & Oncology, Shanghai Children\u2019s Medical Center, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianyi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, National Health Committee Key Laboratory of Pediatric Hematology & Oncology, Shanghai Children\u2019s Medical Center, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhua","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, National Health Committee Key Laboratory of Pediatric Hematology & Oncology, Shanghai Children\u2019s Medical Center, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyu","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, National Health Committee Key Laboratory of Pediatric Hematology & Oncology, Shanghai Children\u2019s Medical Center, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjie","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, National Health Committee Key Laboratory of Pediatric Hematology & Oncology, Shanghai Children\u2019s Medical Center, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, National Health Committee Key Laboratory of Pediatric Hematology & Oncology, Shanghai Children\u2019s Medical Center, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, National Health Committee Key Laboratory of Pediatric Hematology & Oncology, Shanghai Children\u2019s Medical Center, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, National Health Committee Key Laboratory of Pediatric Hematology & Oncology, Shanghai Children\u2019s Medical Center, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liu","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, National Health Committee Key Laboratory of Pediatric Hematology & Oncology, Shanghai Children\u2019s Medical Center, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, National Health Committee Key Laboratory of Pediatric Hematology & Oncology, Shanghai Children\u2019s Medical Center, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, National Health Committee Key Laboratory of Pediatric Hematology & Oncology, Shanghai Children\u2019s Medical Center, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kang","family":"An","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, National Health Committee Key Laboratory of Pediatric Hematology & Oncology, Shanghai Children\u2019s Medical Center, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, National Health Committee Key Laboratory of Pediatric Hematology & Oncology, Shanghai Children\u2019s Medical Center, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, National Health Committee Key Laboratory of Pediatric Hematology & Oncology, Shanghai Children\u2019s Medical Center, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengjuan","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, National Health Committee Key Laboratory of Pediatric Hematology & Oncology, Shanghai Children\u2019s Medical Center, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Children\u2019s Hospital of Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, National Health Committee Key Laboratory of Pediatric Hematology & Oncology, Shanghai Children\u2019s Medical Center, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, National Health Committee Key Laboratory of Pediatric Hematology & Oncology, Shanghai Children\u2019s Medical Center, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanjing","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, National Health Committee Key Laboratory of Pediatric Hematology & Oncology, Shanghai Children\u2019s Medical Center, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benshang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, National Health Committee Key Laboratory of Pediatric Hematology & Oncology, Shanghai Children\u2019s Medical Center, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1007\/s11864-022-01032-5","article-title":"Central nervous system prophylaxis and treatment in acute leukemias","volume":"23","author":"Wu","year":"2022","journal-title":"Curr Treat Options in Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/S2352-3026(23)00088-1","article-title":"Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372\/COG AALL1122): a single-arm, multicentre, phase 2 trial","volume":"10","author":"Hunger","year":"2023","journal-title":"Lancet Haematol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJM200004063421402","article-title":"Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"342","author":"Aric\u00f2","year":"2000","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1001\/jamaoncol.2022.2398","article-title":"Treatment of adults with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia\u2014from intensive chemotherapy combinations to chemotherapy-free regimens: a review","volume":"8","author":"Jabbour","year":"2022","journal-title":"JAMA Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1200\/JCO.2017.76.7228","article-title":"Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia: results of children\u2019s oncology group trial AALL0622","volume":"36","author":"Slayton","year":"2018","journal-title":"JCO"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/leu.2014.30","article-title":"Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: children\u2019s oncology group study AALL0031","volume":"28","author":"Schultz","year":"2014","journal-title":"Leukemia"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/cncr.32558","article-title":"Blinatumomab compared with standard of care for the treatment of adult patients with relapsed\/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia","volume":"126","author":"Rambaldi","year":"2020","journal-title":"Cancer"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"4554","DOI":"10.3390\/cancers14194554","article-title":"Modern management options for ph+ ALL","volume":"14","author":"Ribera","year":"2022","journal-title":"Cancer"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1200\/JCO.20.02262","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41409-020-0982-6","article-title":"Allogeneic haematopoietic stem cell transplantation improves outcome of adults with relapsed\/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia entering remission following CD19 chimeric antigen receptor T cells","volume":"56","author":"Gu","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1182\/blood.2021013733","article-title":"Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL","volume":"139","author":"Qi","year":"2022","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1038\/s41375-024-02319-2","article-title":"Philadelphia-chromosome positive acute lymphoblastic leukemia: ten frequently asked questions","volume":"38","author":"Abou Dalle","year":"2024","journal-title":"Leukemia"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1038\/s41375-021-01277-3","article-title":"Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms","volume":"35","author":"Short","year":"2021","journal-title":"Leukemia"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1200\/JCO.22.01214","article-title":"Coadministration of CD19- and CD22-directed chimeric antigen receptor T-cell therapy in childhood B-cell acute lymphoblastic leukemia: a single-arm, multicenter, phase II trial","volume":"41","author":"Wang","year":"2023","journal-title":"JCO"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"105872","DOI":"10.1016\/j.ebiom.2025.105872","article-title":"Tandem CD19\/CD22 CAR T-cells as potential therapy for children and young adults with high-risk r\/r B-ALL","volume":"118","author":"Gonz\u00e1lez-Mart\u00ednez","year":"2025","journal-title":"EBioMedicine"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41591-021-01497-1","article-title":"CAR T\u202fcells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B\u202fcell acute lymphoblastic leukemia: a phase 1 trial","volume":"27","author":"Cordoba","year":"2021","journal-title":"Nat Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/S1470-2045(23)00436-9","article-title":"Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study","volume":"24","author":"Pan","year":"2023","journal-title":"Lancet Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41408-023-00813-x","article-title":"CD19\/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study","volume":"13","author":"Niu","year":"2023","journal-title":"Blood Cancer J"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/MPH.0000000000002861","article-title":"CAR-T therapy followed by hematopoietic stem cell transplantation can improve survival in children relapsed\/refractory Philadelphia chromosome\u2013positive B-cell acute lymphoblastic leukemia","volume":"46","author":"Li","year":"2024","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-Centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ejca.2020.12.022","article-title":"Long-term follow-up of blinatumomab in patients with relapsed\/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: final analysis of ALCANTARA study","volume":"146","author":"Martinelli","year":"2021","journal-title":"Eur J Cancer"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1182\/blood.2023020621","article-title":"CD19\/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL","volume":"143","author":"Ghorashian","year":"2024","journal-title":"Blood"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.3324\/haematol.2024.286534","article-title":"Five-year outcome of CD19 followed by CD22 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia patients who relapsed after Allo-transplantation","volume":"110","author":"Liu","year":"2025","journal-title":"Haematologica"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11899-025-00769-8","article-title":"Advances and controversies in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia: navigating first-line therapies","volume":"21","author":"Zahra","year":"2026","journal-title":"Curr Hematol Malig Rep"},{"key":"ref30","first-page":"377","article-title":"The role of BCR\/ABL isoforms in the presentation and outcome of patients with Philadelphia-positive acute lymphoblastic leukemia: a seven-year update of the GIMEMA 0496 trial","volume":"91","author":"Cimino","year":"2006","journal-title":"Haematologica"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"5202","DOI":"10.1200\/JCO.2008.21.6408","article-title":"IKZF1 (ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report","volume":"27","author":"Martinelli","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1007\/s00262-020-02829-9","article-title":"Toxicity and effectiveness of CD19 CAR T therapy in children with high-burden central nervous system refractory B-ALL","volume":"70","author":"Tan","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","article-title":"Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1182\/blood-2002-03-0704","article-title":"Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia---results of the prospective multicenter LALA-94 trial","volume":"100","author":"Dombret","year":"2002","journal-title":"Blood"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1182\/blood-2016-03-707562","article-title":"Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"128","author":"Short","year":"2016","journal-title":"Blood"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"4489","DOI":"10.1182\/blood-2009-01-199380","article-title":"Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the international ALL trial MRC UKALLXII\/ECOG2993","volume":"113","author":"Fielding","year":"2009","journal-title":"Blood"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-026-04755-6","article-title":"Anti-CD19 chimeric antigen receptor T-cell therapy for relapsed or refractory Philadelphia chromosome-positive B cell acute lymphoblastic leukemia: a multicenter retrospective study","author":"Yu","year":"2026","journal-title":"BMC Med"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41408-023-00848-0","article-title":"CD19 chimeric antigen receptor T-cell therapy in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia without complete molecular response at 3 months","volume":"13","author":"Yao","year":"2023","journal-title":"Blood Cancer J"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"e250674","DOI":"10.1001\/jamaoncol.2025.0674","article-title":"Dasatinib and CAR T-cell therapy in newly diagnosed Philadelphia chromosome\u2013positive acute lymphoblastic leukemia","volume":"11","author":"Zhang","year":"2025","journal-title":"JAMA Oncol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1815353\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T04:27:32Z","timestamp":1775795252000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1815353\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":40,"alternative-id":["10.3389\/fmed.2026.1815353"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1815353","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"article-number":"1815353"}}